Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $408.0 million.

  • Lyell Immunopharma's Liabilities and Shareholders Equity fell 3411.58% to $408.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 3692.7%. This contributed to the annual value of $490.9 million for FY2024, which is 3455.47% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Liabilities and Shareholders Equity of $408.0 million as of Q3 2025, which was down 3411.58% from $385.5 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Liabilities and Shareholders Equity peaked at $1.2 billion during Q2 2021, and registered a low of $385.5 million during Q2 2025.
  • In the last 5 years, Lyell Immunopharma's Liabilities and Shareholders Equity had a median value of $815.2 million in 2023 and averaged $805.9 million.
  • Per our database at Business Quant, Lyell Immunopharma's Liabilities and Shareholders Equity soared by 2412.54% in 2021 and then crashed by 4107.5% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then dropped by 16.84% to $937.6 million in 2022, then fell by 20.0% to $750.0 million in 2023, then plummeted by 34.55% to $490.9 million in 2024, then dropped by 16.89% to $408.0 million in 2025.
  • Its last three reported values are $408.0 million in Q3 2025, $385.5 million for Q2 2025, and $429.8 million during Q1 2025.